ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Endobronchial Valve Therapy Versus Lung Volume Reduction Surgery in the United States

Thursday, August 28, 2025

Submitted by

Jade Qu

Source

Source Name: The Annals of Thoracic Surgery

Source URL: https://www.annalsthoracicsurgery.org/article/S0003-4975(25)00663-0/abstract

Author(s)

J.W. Awori Hayanga, Xun Luo, Shalini Reddy, J. Hunter Mehaffey, Paul Rothenberg, Dhaval Chauhan, Hakam Rajjoub, Christopher Mascio, Nicholas Baker, Vinay Badhwar, Jason Lamb, Alper Toker

A retrospective study using the US Medicare database compared outcomes for patients with advanced emphysema who underwent endobronchial valve (EBV) therapy vs lung volume reduction surgery (LVRS). After risk adjustment, EBV was associated with higher 30-day mortality, 30-day readmissions, reinterventions, and one-year all-cause mortality rates, despite shorter hospital stays and lower costs compared to LVRS. Most surgeries were minimally invasive, and these findings suggest a need to reevaluate the use of EBV relative to surgery, as EBV patients experienced worse risk-adjusted survival and morbidity outcomes despite having fewer baseline comorbidities than those who underwent LVRS.